Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50Cdc37 complex and direct interactions with amino acids residues of Hsp90

Journal of Nutritional Biochemistry

Volumn 23, Issue 12, 2012, Pages 1617-1626

  Li, Yanyan ^a,b   Karagöz, G Elif ^c   Seo, Young Ho ^a   Zhang, Tao ^a   Jiang, Yiqun ^a   Yu, Yanke ^a   Duarte, Afonso M S ^c   Schwartz, Steven J ^b   Boelens, Rolf ^c   Carroll, Kate ^d   Rüdiger, Stefan G D ^c   Sun, Duxin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Hsp90; NMR; P50Cdc37; Pancreatic cancer; Sulforaphane

Indexed keywords

CELL CYCLE PROTEIN 37; HEAT SHOCK PROTEIN 90; SULFORAPHANE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IC 50; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PANCREAS CANCER; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHAPERONINS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; MOLECULAR CHAPERONES; PANCREATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; THIOCYANATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869090566     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.11.004     Document Type: Article

References (49)

1. Clarke J.D., Dashwood R.H., Ho E. Multi-targeted prevention of cancer by sulforaphane. Cancer Lett 2008, 269:291-304.
2. Conaway C.C., Wang C.X., Pittman B., et al. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res 2005, 65:8548-8557.
3. Fahey J.W., Zhang Y., Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A 1997, 94:10367-10372.
4. Li Y., Zhang T., Korkaya H., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res 2010, 16:2580-2590.
5. Juge N., Mithen R.F., Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci 2007, 64:1105-1127.
6. Zhang Y., Tang L. Discovery and development of sulforaphane as a cancer chemopreventive phytochemical. Acta Pharmacol Sin 2007, 28:1343-1354.
7. Chaudhuri D., Orsulic S., Ashok B.T. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Mol Cancer Ther 2007, 6:334-345.
8. Gibbs A., Schwartzman J., Deng V., Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A 2009, 106:16663-16668.
9. Kim S.H., Singh S.V. d,l-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther 2009, 8:1946-1954.
10. Yao H., Wang H., Zhang Z., Jiang B.H., Luo J., Shi X. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells. Int J Cancer 2008, 123:1255-1261.
11. Smith J.R., Workman P. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning. Cell Cycle 2009, 8:362-372.
12. Kamal A., Boehm M.F., Burrows F.J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004, 10:283-290.
13. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
14. Karagoz G.E., Duarte A.M., Ippel H., et al. N-terminal domain of human Hsp90 triggers binding to the cochaperone p23. Proc Natl Acad Sci U S A 2011, 108:580-585.
15. Tugarinov V., Hwang P.M., Kay L.E. Nuclear magnetic resonance spectroscopy of high-molecular-weight proteins. Annu Rev Biochem 2004, 73:107-146.
16. Butz J., Wickstrom E., Edwards J. Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. BMC Biotechnol 2003, 3:11.
17. Mohiuddin M., Chendil D., Dey S., Alcock R.A., Regine W., Ahmed M.M. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells. Anticancer Res 2002, 22:825-830.
18. Alcock R.A., Dey S., Chendil D., et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene 2002, 21:7883-7890.
19. Neckers L. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem 2003, 10:733-739.
20. Bertelsen E.B., Chang L., Gestwicki J.E., Zuiderweg E.R. Solution conformation of wild-type E. coli Hsp70 (DnaK) chaperone complexed with ADP and substrate. Proc Natl Acad Sci U S A 2009, 106:8471-8476.
21. Sprangers R., Kay L.E. Quantitative dynamics and binding studies of the 20S proteasome by NMR. Nature 2007, 445:618-622.
22. Koorstra J.B., Hustinx S.R., Offerhaus G.J., Maitra A. Pancreatic carcinogenesis. Pancreatology 2008, 8:110-125.
23. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.
24. Barton C.M., Staddon S.L., Hughes C.M., et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991, 64:1076-1082.
25. Schlieman M.G., Fahy B.N., Ramsamooj R., Beckett L., Bold R.J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003, 89:2110-2115.
26. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988, 53:549-554.
27. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
28. Reichert M., Saur D., Hamacher R., Schmid R.M., Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007, 67:4149-4156.
29. Altomare D.A., Tanno S., De Rienzo A., et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002, 87:470-476.
30. Petri N., Tannergren C., Holst B., et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos 2003, 31:805-813.
31. Ye L., Dinkova-Kostova A.T., Wade K.L., Zhang Y., Shapiro T.A., Talalay P. Quantitative determination of dithiocarbamates in human plasma, serum, erythrocytes and urine: pharmacokinetics of broccoli sprout isothiocyanates in humans. Clin Chim Acta 2002, 316:43-53.
32. Shapiro T.A., Fahey J.W., Dinkova-Kostova A.T., et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 2006, 55:53-62.
33. Kensler T.W., Chen J.G., Egner P.A., et al. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol Biomarkers Prev 2005, 14:2605-2613.
34. Prodromou C., Roe S.M., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90:65-75.
35. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89:239-250.
36. Workman P., Burrows F., Neckers L., Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216.
37. Neckers L. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb Exp Pharmacol 2006, 259-277.
38. Whitesell L., Mimnaugh E.G., De Costa B., Myers C.E., Neckers L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994, 91:8324-8328.
39. Usmani S.Z., Bona R., Li Z. 17 AAG for HSP90 inhibition in cancer - from bench to bedside. Curr Mol Med 2009, 9:654-664.
40. Zhang T., Hamza A., Cao X., et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008, 7:162-170.
41. Yu Y., Hamza A., Zhang T., et al. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 2009.
42. Zhang T., Li Y., Yu Y., Zou P., Jiang Y., Sun D. Characterization of celastrol to inhibit HSP90 and CDC37 interaction. J Biol Chem 2009.
43. Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 2000, 21:1175-1182.
44. Dickinson S.E., Melton T.F., Olson E.R., Zhang J., Saboda K., Bowden G.T. Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. Cancer Res 2009, 69:7103-7110.
45. Hong F., Freeman M.L., Liebler D.C. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol 2005, 18:1917-1926.
46. Roe S.M., Ali M.M., Meyer P., et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004, 116:87-98.
47. Jiang Y., Bernard D., Yu Y., et al. Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions. J Biol Chem 2010, 285:21023-21036.
48. Rao R., Fiskus W., Yang Y., et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008, 112:1886-1893.
49. Mi L., Hood B.L., Stewart N.A., et al. Identification of potential protein targets of isothiocyanates by proteomics. Chem Res Toxicol 2011, 24:1735-1743.